A short list of seasonal tips for people taking GLP-1 drugs as the weather turns. Generic advice, no details on who made it or what it covers.
Recap by typeshit. Video by TikTok on TikTok.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
People with conditions the drugs are approved to treat get sent back to Part D, where copays can hit $200 to $600 a month. One New Jersey patient was rejected despite a BMI of 42.
Most IV sessions run $170 to $280. California's pharmacy board has called these clinics largely unregulated, and experts question the benefits.
Loading…